Value for money from HPV vaccination and cervical screening

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 828-830

  Ashton, Toni ^a   Sopina, Elizaveta ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cervical screening; Human papillomavirus (HPV) vaccination; Prevention of cervical cancer; Value for money

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; INFECTION PREVENTION; INFECTION RATE; NONHUMAN; NOTE; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; RISK REDUCTION; UTERINE CERVIX CANCER; VACCINATION;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84863705532     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19807     Document Type: Note

References (14)

1. Haas M, Ashton T, Blum K, Christiansen T, Conis E, Crivelli L, et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009; 92:288-95; PMID:19505744; http://dx.doi.org/10.1016/j.healthpol.2009.05.002.
2. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008; 26:6529-41; PMID:18805453; http://dx.doi.org/10.1016/j.vaccine.2008.08.067.
3. Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010; 7:320-4; PMID:20719221; http://dx.doi.org/10.1071/SH09153.
4. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Health 2010; 7:352-8; PMID:20719227; http://dx.doi.org/10.1071/SH10018.
5. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-73; PMID:16670757; http://dx.doi.org/10.1172/JCI28607.
6. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5.
7. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502; PMID:19837728; http://dx.doi.org/10. 1136/sti.2009.037788.
8. Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician 2000; 61:1369-76; PMID:10735343.
9. National Cervical Cancer Coalition. Global initiative against HPV and cervical cancer.
10. Gustafsson L, Pontén J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8:755-63; PMID:9328198; http://dx.doi.org/10.1023/A: 1018435522475.
11. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27:127-47; http://dx.doi.org/10.2165/00019053-200927020- 00004; PMID:19254046.
12. Sopina E, Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care 2011; 27:290-7; PMID:21936972; http://dx.doi.org/10.1017/S0266462311000456.
13. Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012; 30:425-35; PMID:22075091; http://dx.doi.org/10.1016/j.vaccine.2011.10.067.
14. National Screening Unit. Guidelines for Cervical Screening in New Zealand - Incorporating the Management of Women with Abnormal Cervical Smears. Wellington: National Screening Unit, Ministry of Health, 2008.